F

ollowing a long-running probe, Aegerion Pharmaceuticals has agreed to pay $40 million to settle civil and criminal charges of illegally marketing a pricey cholesterol medicine, failing to adhere to a regulatory safety program, and misleading investors.

Specifically, the company was accused of “unlawfully” marketing Juxtapid, which costs up to $300,000 a year and was approved to treat a rare and inherited form of high cholesterol. The U.S. Department of Justice charged that sales reps were instructed to promote the medicine for treating very high cholesterol more generally, to widen the pool of potential patients and boost sales, but without adequate directions, according to court documents.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.